RG
PRME icon

Redmile Group’s Prime Medicine PRME Stock Holding History

Redmile Group’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.13M Sell
1,389,632
-201,200
-13% -$668K 0.34% 33
2026
Q1 		$5.54M Buy
+1,590,832
New +$6.05M 0.37% 28
2025
Q4 		– Sell
-87,118
Closed -$483K – 40
2025
Q3 		$483K Sell
87,118
-1,987,232
-96% -$8.07M 0.05% 38
2025
Q2 		$5.12M Hold
2,074,350
– – 0.55% 33
2025
Q1 		$4.13M Hold
2,074,350
– – 0.39% 40
2024
Q4 		$6.06M Hold
2,074,350
– – 0.42% 44
2024
Q3 		$8.03M Hold
2,074,350
– – 0.47% 40
2024
Q2 		$10.7M Hold
2,074,350
– – 0.64% 38
2024
Q1 		$14.5M Buy
2,074,350
+750,000
+57% +$5.69M 0.53% 48
2023
Q4 		$11.7M Hold
1,324,350
– – 0.42% 49
2023
Q3 		$12.6M Hold
1,324,350
– – 0.6% 40
2023
Q2 		$19.4M Sell
1,324,350
-668,493
-34% -$9.33M 0.74% 40
2023
Q1 		$24.5M Sell
1,992,843
-216,507
-10% -$3.53M 1.06% 37
2022
Q4 		$41M Buy
+2,209,350
New +$39.9M 1.68% 21

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Redmile Group's PRME Position: Q2 2026 in Review

Redmile Group reduced its Prime Medicine (PRME) stake by 13% in Q2 2026, selling an estimated $668K and leaving 1,389,632 shares worth $5.13M. The position accounts for 0.34% of the portfolio, ranked #33.

Redmile Group first reported a position in PRME in Q4 2022 and has held it in 14 quarters since. The position peaked at $41M in Q4 2022. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Redmile Group held 1,389,632 shares of Prime Medicine worth $5.13M as of Q2 2026.
  • Redmile Group sold 201,200 Prime Medicine shares in Q2 2026, an estimated $668K.
  • Prime Medicine made up 0.34% of Redmile Group's portfolio in Q2 2026, its #33 holding.
  • Redmile Group first reported a position in Prime Medicine in Q4 2022 and has held it in 14 quarters since.
  • Redmile Group's Prime Medicine position peaked at $41M in Q4 2022.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Redmile Group's 13F filing for Q2 2026, filed 14 Aug 2026.